Clinical Trials Directory

Trials / Completed

CompletedNCT01756651

Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures

A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Richard C Reznichek, MD · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of intranasally-administrated fentanyl pectin spray (Lazanda®)given to decrease the pain during cystoscopy (the passage of a telescopic instrument into the bladder for purpose of diagnosing the cause of blood in the urine, urinary complaints or any other problems with the urinary bladder). The current standard practice is to use Lidocaine jelly (a local anesthetic) given through the urethra to lubricate and decrease local pain. In this study, an additional medicine (Lazanda®) is used to reduce pain that occurs during and after the above procedure.

Detailed description

In this prospective study, twenty subjects will be enrolled. The first ten will receive a dose of 100mcg pectin fentanyl nasal spray (Lazanda®). The second ten will receive a dose of 200mcg pectin fentanyl nasal spray (Lazanda®) if the 100mcg was well tolerated in the first ten. In all cases, Lidocaine jelly is used as an local anesthetic in the urethra.

Conditions

Interventions

TypeNameDescription
DRUGFentanyl pectincomparison of Intranasal fentanyl 100mcg vs 200 mcg.

Timeline

Start date
2013-02-01
Primary completion
2016-05-10
Completion
2016-05-10
First posted
2012-12-27
Last updated
2017-05-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01756651. Inclusion in this directory is not an endorsement.